DDInter1622 DDInter1435
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvastatin
Rosuvastatin {u} (Compound) treats {v} (Disease) atherosclerosis
Rosuvastatin {u} (Compound) binds {v} (Gene) ABCC1
Rosuvastatin {u} (Compound) upregulates {v} (Gene) STX1A
Rosuvastatin {u} (Compound) downregulates {v} (Gene) CYR61
Rosuvastatin {u} (Compound) causes {v} (Side Effect) Influenza
Rosuvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Desogestrel
Rosuvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norgestrel
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Rosuvastatin {u} may lead to a major life threatening interaction when taken with {v} Nelfinavir
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Rosuvastatin (Compound) treats atherosclerosis (Disease)
Rosuvastatin (Compound) binds ABCC1 (Gene)
Rosuvastatin (Compound) upregulates STX1A (Gene)
Rosuvastatin (Compound) downregulates CYR61 (Gene)
Rosuvastatin (Compound) causes Influenza (Side Effect)
Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Desogestrel
Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Rosuvastatin may lead to a major life threatening interaction when taken with Nelfinavir